Novel Aromatic Heterocycles for Dual MAO A and B Inhibitors: A Promising Strategy for Parkinson's Disease Treatment

Abstract

Recent advancements in the synthesis of aromatic heterocycles have shown promise in the inhibition of monoamine oxidase (MAO) A and B enzymes implicated in the pathophysiology of Parkinson's disease (PD). These heterocyclic compounds are of particular interest due to their structural diversity and significant pharmacological potential.This review discusses various strategies for enhancing MAO inhibitory activity, emphasizing positional modifications. Notable progress includes the development of thiazole‐based and imidazole‐based heterocycles with detailed exploration of their synthetic methodologies and structure–activity relationships. These compounds have demonstrated potential in targeting the metabolism of neurotransmitters, particularly dopamine, which is crucial for managing PD symptoms.The synthesis of aromatic heterocycles targeting MAO A and B inhibition offers a promising pathway for developing novel therapeutics for Parkinson's disease. The structural diversity and pharmacological potential of these compounds, combined with their ability to modulate neurotransmitter levels, present a hopeful avenue for more effective PD management. However, further research, including structure‐based design and in vivo validation, is essential to fully realize their therapeutic efficacy and improve treatment outcomes for Parkinson's disease.